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Abstract 
 
Human luteinizing hormone (LH) and chorionic gonadotropin (hCG) have been considered 
biologically equivalent because of their structural similarities and their binding to the same 
receptor; the LH/CGR. However, accumulating evidence suggest that LH/CGR differentially 
responds to the two hormones triggering differential intracellular signaling and steroidogenesis. The 
mechanistic basis of such differential responses remains mostly unknown. Here, we compared the 
abilities of recombinant rhLH and rhCG to elicit cAMP, β-arrestin 2 activation, and steroidogenesis 
in HEK293 cells and mouse Leydig tumor cells (mLTC-1). For this, BRET and FRET technologies 
were used allowing quantitative analyses of hormone activities in real-time and in living cells. Our 
data indicate that rhLH and rhCG differentially promote cell responses mediated by LH/CGR 
revealing interesting divergences in their potencies, efficacies and kinetics: rhCG was more potent 
than rhLH in both HEK293 and mLTC-1 cells. Interestingly, partial effects of rhLH were found on 
β-arrestin recruitment and on progesterone production compared to rhCG. Such a link was further 
supported by knockdown experiments. These pharmacological differences demonstrate that rhLH 
and rhCG act as natural biased agonists. The discovery of novel mechanisms associated with 
gonadotropin-specific action may ultimately help improve and personalize assisted reproduction 
technologies. 
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Introduction 
 
Luteinizing hormone (LH) and human chorionic gonadotropin (hCG) are two heterodimeric 
glycoprotein hormones playing key roles in human reproduction. They are produced by the pituitary 
gland (LH) and placenta (hCG) and circulate as mixtures of differentially glycosylated isoforms 
which present different half-lives and bioactivities 1-3. Both hCG and hLH bind to luteinizing 
hormone/choriogonadotropin hormone receptor (LH/CGR) in human and LHR in non-human 
species which are mainly expressed in the ovary and testis. In normal female cycle, LH is involved 
in late follicular maturation and ovulation and it also triggers corpus luteum steroidogenic activity. 
hCG is responsible for maintaining steroidogenic activity by corpus luteum over the first four 
months of pregnancy in women. hCG also inhibits LH and FSH secretion and triggers 
steroidogenesis in fetal gonads 4,5. LH/CGR belongs to a subgroup of class A (rhodopsin-like) 
GPCRs characterized by the presence of multiple leucine-rich repeats (LRRs) in their extracellular 
amino-terminal domain. Regarding its signaling, LH/CGR is known to mediate the canonical G 
protein-mediated signaling pathway through coupling to heterotrimeric Gαs protein which activates 
adenylate cyclase. It results in cAMP accumulation and activation of protein kinase A (PKA), as 
well as in the exchange protein directly activated by cAMP (EPAC). This, in turn, triggers the 
activation of multiple downstream kinases that modulate the nuclear activity of cAMP response 
element-binding protein (CREB) and the expression of the genes involved in the physiological 
responses to these hormones. Besides, LH/CGR was one of the first GPCRs shown to 
independently activate two G proteins, leading to both adenylyl cyclase and phospholipase C 
activation through functional coupling to Gαs and Gαq, respectively 6,7. More recently, LH/CGR 
has been also reported to engage a multiplicity of G protein-independent pathways 8 including β-
arrestin-dependent pathways 9-11. For many years, β-arrestins have been considered exclusively as 
silencers of the GPCRs signaling, prompting ligand-induced receptor internalization and trafficking 
12,13. Now it is well recognized that β-arrestins regulate GPCR signaling and trafficking and are also 
able to engage G protein-independent signaling, the most studied of which being ERK1/2 pathway 
12-14. The implication of β-arrestins in trafficking and signaling of gonadotropin receptors has also 
been reported 11,15-21. 
For many years, LH and hCG have been assumed to be equivalent, even though distinct 
physiological 5,22, molecular 23,24 and pharmacological 25,26 features were described 3,27. Importantly, 
the phenomenon of biased signaling implies that the binding of a given ligand can stabilize a subset 
of activated conformations of the receptor thereby leading to a selective modulation of downstream 
signaling pathways. This has been reported for numerous GPCRs 14,28-30. In line with this emerging 
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concept, it has been recently proposed that LH and hCG produced as multiple glycosylated isoforms 
could potentially trigger selective transduction mechanisms at the LH/CGR 1,8. Recent lines of 
evidence support this hypothesis, showing that, although their structures are similar and they shared 
the same receptor, LH and hCG elicit divergent signaling in several cell models 27. A genomic 
deletion resulting in the complete absence of exon 10 of LH/CGR found in a hypogonadic patient 
with type II Leydig cell hypoplasia 31 impaired LH-, but not hCG-induced cAMP production, 
without affecting ligand binding 32. More recently, it has been reported in human granulosa cells 
that hCG displays higher potency than LH on the cAMP/PKA pathway as well as on 
steroidogenesis, whereas LH is more potent than hCG on ERK1/2 and Akt phosphorylation as well 
as on related gene expression 33. The proliferative and steroidogenic/pro-apoptotic effects mediated 
by LH and hCG in vitro, respectively, are amplified by FSH co-treatment 34. In fact, in goat ovarian 
granulosa cells, prolonged LH treatment promotes growth and proliferation whereas hCG leads to 
higher levels of cAMP and decreased proliferation 35.  
Despite these recent advances, the potential of hCG and LH to differentially activate Gαs 
and β-arrestin-dependent pathways at the LH/CGR and LHR has not been evaluated. In addition, 
the relative contributions of these transduction mechanisms to steroidogenesis are still unknown. In 
the present study, we used a series of bioluminescence and time-resolved resonance energy transfer 
(BRET and TR-FRET) and reporter assays to quantitatively assess the signaling promoted by rhCG 
and rhLH in real-time and living cells as previously reported 10,11. The canonical Gαs/cAMP 
pathway as well as β-arrestin 2 recruitment were analyzed upon the activation of human LH/CGR 
transiently expressed in HEK293 cells or LHR endogenously expressed in murine Leydig tumor 
cell line (mLTC-1) 11,36. In addition, the degree of bias between rhCG- and rhLH-mediated 
responses was quantified using the operational model of Black and Leff 37 and previously detailed 
procedures 11,38. 
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Materials and Methods 
 
Recombinant gonadotropins: Human recombinant LH (Luveris®) and rhCG (Ovitrelle®) were 
kindly provided by Merck KGaA (Darmstadt, Germany). Molar concentrations of the recombinant 
rhCG and rhLH were calculated based on their respective specific activities (6500 and 5360 IU) and 
molecular weights (37 and 30 kDa).  
 
Cell Culture and Transfection: HEK293 cells were grown in complete DMEM medium 
supplemented with 10% (v/v) fetal bovine serum, 4.5 g/l glucose, 100 U/ml penicillin, 0.1 mg/ml 
streptomycin, and 1 mM glutamine (Invitrogen, Carlsbad, CA, USA). mLTC-1 cells (ATCC CRL-
2065, LCG Standards, Molsheim, France) were grown in complete RPMI medium supplemented 
with 10% (v/v) fetal bovine serum, 50 µg/ml gentamicin, 10 units/ml penicillin and 10µg/ml 
streptomycin. Transient transfections were performed by reverse transfection in 96-well plate using 
Metafectene PRO (Biontex, München, Germany) following the manufacturer’s protocol and using 
105 cells, 100 ng of total plasmids and 0.5 µl of Metafectene PRO per well. 
 
Small interfering RNA transfection: The siRNA sequence 5’-
AAAGCCUUCUGUGCUGAGAAC-3’ was used to target mouse β-arrestin 1 (position 439-459 
relative to the start codon) whereas sequence 5’-AAACCUGUGCCUUCCGCUAUG-3’ was used 
to target mouse β-arrestin 2 (position 175-193 relative to the start codon) 39. One small RNA duplex 
with no silencing effect was used as a control (5’-UUCUCCGAACGUGUCACGU-3’). The 
siRNAs were synthesized by GE Healthcare Dharmacon (Velizy-Villacoublay, France). Early 
passage mLTC-1 cells at 30% confluency in 100 mm dishes were transiently transfected with 
GeneSilencer following the manufacturer’s recommendations (Genlantis, San Diego, CA, USA). 
Forty-eight hours after transfection, cells were seeded into assay plates. All assays were performed 
three days after transfection. 
 
BRET sensors: In order to measure cAMP real-time response in living cells, HEK293 cells were 
transiently transfected with two plasmids coding for hLH/CGR (kindly provided by A. Ulloa-
Aguirre, Universidad Nacional Autónoma de México, México) and the BRET-based cAMP sensor 
CAMYEL (kindly provided by L.I. Jiang, University of Texas, Texas, USA) as previously reported 
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10,11. For mLTC-1 cells, only CAMYEL plasmid was transfected since they naturally express the 
endogenous LHR.  
For the assessment of β-arrestin 2 recruitment, HEK293 cells were transiently co-transfected 
with plasmids coding for hLH/CGR C-terminally fused to the BRET donor Rluc8 (kindly provided 
by Dr. A. Hanyaloglu, Imperial College, London, UK) and for β-arrestin 2 N-terminally fused to the 
BRET acceptor yPET (kindly provided by Dr. M.G. Scott, Cochin Institute, Paris, France). Upon 
rhCG and rhLH stimulation, β-arrestin 2 translocates to the receptor, leading to energy transfer 
between Rluc8 and yPET, and as a consequence, to dose-dependent increases in BRET signals. The 
conformational rearrangements within β-arrestin 2 were measured using β-arrestin 2 double 
brilliance sensor 40-42. For this, HEK293 cells were transiently co-transfected with the plasmids 
coding for hLH/CGR and for Rluc8-β-arrestin 2-RGFP fusion protein (kindly provided by Dr. R. 
Jockers, Cochin Institute, Paris, France). Then, changes in intramolecular BRET signals within 
sensor were monitored upon cell stimulation with increasing doses of rhCG and rhLH. 
 
Cell stimulations and BRET measurements: For the end-point dose-response experiments, 
medium was aspirated and cells were re-suspended in 40 µl/well of PBS 1X, 1 mM HEPES. Cells 
were incubated for 30 minutes at 37°C in a total volume of 40 µl/well of PBS 1X, 1 mM HEPES 
containing or not increasing concentrations of rhCG and rhLH. BRET measurements were 
performed upon addition of 10 µl/well of 5 µM Coelenterazine h (Interchim, Montluçon, France), 
using Mithras LB 943 plate reader (Berthold Technologies GmbH & Co. Wildbad, Germany). For 
the real-time kinetics, cells were re-suspended in 60 µl/well of PBS 1X, 1 mM HEPES and, for 
cAMP kinetics, 200 µM IBMX. BRET measurement was immediately performed upon addition of 
20 µl/well of EC50 concentrations of rhCG and rhLH as previously calculated in dose-response 
experiments, and 20 µl/well of coelenterazine h. 
 
Cre-dependent reporter assay: HEK293 cells were transiently transfected with hLH/CGR and the 
pSOM-Luc plasmid expressing the firefly luciferase reporter gene under the control of the cAMP 
Responsive Element of the somatostatin promoter region 43. mLTC-1 cells were transiently 
transfected with the pSOM-Luc plasmid alone. After 48-hours, cells were split into 96-well plates. 
The day after, cells were stimulated 6 hours with increasing doses of hormones, then washed twice 
with ice-cold PBS and lysed in 200 µl of lysis buffer (Promega, Madison, WI, USA). Luciferase 
activity was measured using the luciferase assay system supplied by Promega. An aliquot (20 µl) of 
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each sample was mixed with 50 µl of luciferase assay reagent and the emitted light was measured in 
Mithras LB 943 plate reader. Values were expressed in relative luciferase activity units (RLU). 
 
Steroid measurements: Progesterone and testosterone levels were measured in the supernatants of 
mLTC-1 cells cultured in complete RPMI medium. For progesterone, cells were first seeded in 48-
well plates (105 cells/well) for three days and then re-suspended in serum-free RPMI for one hour 
and stimulated or not with increasing doses of rhCG and rhLH for 3 hours. Cell supernatants were 
collected and stored at -20°C until analysis. Progesterone production was measured with a home-
made competitive ELISA assay 44. Briefly, a 96-wells plate was coated overnight at 4°C with a goat 
anti-mouse IgG antibody, 10 ng/well (UP462140, Interchim, Montluçon, France). After three 
washes in PBS 1X containing 0.1% Tween 20, non-specific sites were saturated 1 hour with 200 
µl/well of PBS-Tween 20 supplemented with 0.2% BSA. Standard progesterone (Q2600, Steraloids, 
USA) in PBS-Tween 20-BSA or mLTC-1 cells supernatants (25µl per well of 1:50 or 1:100 
dilution) were then plated on the empty plate. Progesterone-11-Hemisuccinate-HRP (Interchim) 
were added, together with 36 ng/well of mouse anti-P4 antibody (AbD Serotec, Biogenesis, 
Interchim). The plate was incubated for 4 hours at room temperature, washed and 100 µl/well of 
TMB ELISA substrate standard solution (Interchim) was added. The mixture was incubated for 20 
min at room temperature in the dark. The reaction was stopped with 2N H2SO4 and absorbance was 
measured at 450 nm using SunriseTM absorbance reader (Tecan, France). 
Testosterone levels were measured by using an HTRF®-based assay kit (CisBio Bioassays, 
Codolet, France) following the manufacturer’s protocol and as previously described 11. Briefly, cells 
were seeded in 96-well plate (104 cells/well), starved overnight in serum-free RPMI medium and 
incubated 3 hours at 37°C in 100 µL/well of serum-free RMPI medium containing or not increasing 
concentrations of rhCG and rhLH. Then 10 µl of culture supernatants were transferred into 384-well 
and mixed with 10 µl of a mixture of HTRF mix containing an anti-testosterone antibody and 
testosterone labeled with Terbium and d2 fluorophores, respectively. TR-FRET signals were 
detected using Mithras LB 943 plate reader (Berthold Technologies GmbH & Co. Wildbad, 
Germany). 
 
 
cAMP HTRF-based assay: Intracellular cAMP levels were measured using a homogeneous time-
resolved fluorescence (HTRF®) assay kit (CisBio Bioassays) 10,11 according to the manufacturer’s 
instructions.  
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Data analysis: BRET data were represented as “Induced BRET Changes” by subtracting the 540 
nm/480 nm ratio of the non-treated cells from the same ratio of cells stimulated with increasing 
doses of rhCG and rhLH. The % of responses in BRET and steroid measurement were obtained by 
taking as 100% the maximal response of rhCG at 10 nM in the different assays. All the results were 
fitted following the appropriate nonlinear regression equations using GraphPad Prism software (San 
Diego, CA, USA). Statistical analyses were performed with unpaired t-test (for the Emax and EC50 
values) in HEK293 and mLTC-1 cells and Two-way ANOVA (for siRNA β-arrestin data in mLTC-
1 cells), both using the GraphPad Prism software. 
 
Bias calculation: The bias factor (B.F.) was obtained after statistical fitting of the data to the 
operational model reported by Black and Leff 37, as previously reported 11. 
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Results 
LH/CGR-promoted cAMP Response: To compare the respective efficacies and potencies of 
rhCG and rhLH, we first assessed the ability of either hormone to elicit the accumulation of cAMP, 
the prototypical second messenger produced upon coupling and activation of the heterotrimeric Gαs 
protein by LH/CGR. For this purpose, HEK293 cells transiently co-expressing human LH/CGR and 
the BRET-based cAMP sensor (CAMYEL) were used as previously reported 10,11. Changes in 
BRET signal were monitored in living cells after 30 minutes of incubation with increasing doses of 
rhCG and rhLH. As expected, both hormones showed very potent effects on the cAMP signaling 
pathway with EC50 values in the pM range as previously shown 10,11 (Fig.1A)(Table 1). Consistent 
with previous reports, the rhCG dose-response curve is significantly shifted towards the lower doses 
compared to that of rhLH 33. Indeed, the EC50 values of rhCG response was found approximately 16 
times lower than that of rhLH (p<0.0001; n=7)(Table 1). By contrast, at the saturating doses both 
hormones promoted similar maximal cAMP responses indicating that both act as full agonists on 
LH/CGR-promoted cAMP production. We also investigated cAMP accumulation in real-time 
kinetics by stimulating cells with different concentrations (0.05, 0.5, and 5 nM) of rhCG and rhLH 
to cover the EC50 and sub-maximal doses according to the dose curves shown in Fig.1A. As shown 
in Fig.1B, a relationship between the doses and the kinetics was observed with faster and saturating 
responses obtained when increasing doses were used. Indeed, when rhCG and rhLH were compared 
at their respective sub-saturating doses (i.e.: 0.01 nM for rhCG and 0.5 nM for rhLH), both 
promoted a rapid cAMP response with no difference in their kinetics (t1/2 around 1 min) (Fig.1B). 
The response reached a plateau even after 30 minutes of stimulation (Fig.1B) and this cannot be due 
to a saturation of the cAMP response in our system. In fact, at a higher and saturating dose of both 
hormones (5 nM), the cAMP response was further increased with faster (t1/2 value around 0.5 min) 
and equivalent kinetics for both hormones (Fig.1B).  
To investigate the cAMP pathway on endogenously expressed LHR, we used a mouse 
Leydig tumor cell line (mLTC-1)45 either transfected with CAMYEL sensor (Fig.1C) or not 
(Fig.1D), as previously reported 10,11. Again, BRET measurements revealed rhCG dose-response 
curve shifted towards the lower doses compared to rhLH (Fig.1C). Specifically, the EC50 value of 
rhCG was approximately 6 times lower than that of rhLH (p=0.0067; n=5) (Table 2). To further 
confirm these data and to exclude any artifact due to the transfection of CAMYEL sensor in mLTC-
1 cells, we also measured cAMP levels in native cells using HTRF-based assay, which does not 
require any cell transfection. We found a similar pattern of rhCG- and rhLH-induced cAMP 
responses (Fig.1D). It is worth noting that consistent with HEK293 cell data, rhCG and rhLH 
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promoted similar maximal cAMP responses in mLTC-1 cells despite the differences in their 
potencies confirming that both are full agonists for cAMP pathway (Fig.1C and D)(Table 2). 
  
β-arrestin 2 recruitment and activation: β-arrestins are known to play important roles not only in 
desensitization/internalization of GPCRs but also in their signaling 12-14. Here, we examined the 
recruitment of β-arrestin 2 upon exposure to increasing doses of rhCG and rhLH using BRET 
technology as previously reported 10,11. HEK293 cells were transiently co-transfected with plasmids 
coding for hLH/CGR-Rluc8 and for yPET-β-arrestin 2 fusion proteins and BRET measurements 
were performed in a dose-dependent manner and in living cells. As shown in Fig.2A, rhCG and 
rhLH stimulation significantly promoted β-arrestin 2 recruitment to hLH/CGR in a dose-dependent 
manner with the EC50 value of rhCG 12 times lower than that of rhLH (p=0.044; n=5)(Table 1). 
The significant difference in the two hormone potencies is consistent with the data on cAMP 
pathway (Fig.1)(Table 1). Low potencies were found for both hormones on β-arrestin recruitment 
compared to cAMP responses consistent with our previous report indicating that a higher receptor 
occupancy rate is needed to engage β-arrestin recruitment 10,11. Interestingly, our data reveal that 
rhLH seems to exhibit partial agonistic activity compared to rhCG (p=0.0104; n=5)(Fig.2A)(Table 
1). Real-time kinetic analysis of BRET signals in cells stimulated with either EC50 (10 nM and 50 
nM) or saturating (500 nM) concentrations of both rhCG and rhLH, showed a significant difference 
in β-arrestin 2 recruitment kinetics between the two hormones with t1/2 values of 6.15 ± 0.17 min 
and 13.32 ± 0.32 min with 500 nM of rhCG and rhLH, respectively (Fig.2B). These kinetic data are 
in keeping with the partial activity of rhLH compared to rhCG on β-arrestin recruitment even at the 
saturating doses of the hormone (Fig.2B).  
Next, we investigated the impact of hLH/CGR activation by rhCG or rhLH on β-arrestin 2 
conformations using a previously reported double brilliance β-arrestin 2 BRET sensor 40-42. In this 
sensor, β-arrestin 2 is fused with both a BRET donor and acceptor. Therefore, any change in the 
intramolecular BRET signals reflects a conformational change in β-arrestin 2. Interestingly, real-
time kinetic analyses with 0.25 µM of hormones showed stronger induction of conformational 
changes under LH than rhCG treatment within β-arrestin sensor (Fig.2C). However, no significant 
difference in the half-time (around 12 minutes) between the two hormones was observed (Fig.2C). 
Such a difference between rhCG and rhLH on β-arrestin conformation was observed at different 
concentrations of the hormones (Fig.2D). Together, the data with β-arrestins are consistent with the 
different sensitivity of LH/CGR to rhCG and rhLH suggesting the existence of hormone-specific 
receptor conformation which could in turn impact β-arrestin conformation.  
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LHR-promoted integrated responses: To further assess the impact of the differences elicited by 
the two hormones at the transductional level, we sought to measure downstream read-outs in the 
signaling pathways. In HEK293 cells, we used a cre-dependent reporter gene, pSOM-Luc, as an 
indicator of LH/CGR-induced transcriptional activation 11,43. As shown in Fig.3A, both hormones 
showed clear dose-dependent activation of luciferase activity with EC50 of rhCG almost 5 times 
lower than that of rhLH (p=0.0004; n=3)(Table 1). By contrast, the two hormones showed similar 
maximal responses expressed in relative luciferase activity (Fig.3A)(Table 1). These observations 
are consistent with the cAMP data in HEK293 and mLTC-1 cells as shown in Fig.1. 
Next, we explored more distal responses to rhCG and rhLH in mLTC-1 cells endogenously 
expressing LHR. For this, we measured pSOM-Luc activation in Cre reporter assay (Fig.3B), 
progesterone (Fig.3C) and testosterone (Fig.3D) responses upon stimulation with increasing doses 
of rhCG and rhLH. In the Cre reporter assay, we observed a significant shift (p=0.0202; n=4) 
similar to the one observed in HEK293 cells with rhCG being more potent than rhLH, 
(Fig.3B)(Table 2). In progesterone assay, we found that the EC50 of rhCG was approximately 15 
times lower than that of rhLH (p=0.0011; n=3)(Fig.3C)(Table 2). This observation is in agreement 
with cAMP data (Fig.1), β-arrestin data (Fig.2A), and Cre-luciferase-based cAMP assay (Fig.3A) 
data confirming that rhCG is more potent than rhLH on LH/CGR. Interestingly, the maximal 
progesterone produced by rhLH was only 49.8 ± 2.9 % (p<0.0001; n=3) of that promoted by rhCG, 
indicating a partial response of rhLH on progesterone synthesis (Fig.3C)(Table 2). Such a partial 
response of rhLH is consistent with that observed for LH/CGR-promoted β-arrestin 2 recruitment 
(Fig.2A). In the case of testosterone, we also observed a higher potency of rhCG (≈13 folds) 
compared to rhLH, (p=0.0084; n=4)(Fig.3D)(Table 2), which is consistent with progesterone data 
(Fig.3C), cAMP responses in HEK293 and mLTC-1 cells (Fig.1A and C) as well as β-arrestin in 
HEK293 cells (Fig.2A). We also noticed that both hormones were clearly more potent at activating 
testosterone than progesterone production (Table 2). However, by contrast to progesterone 
response, there was no significant difference in the maximal testosterone response between the two 
hormones (p=0.3848; n=4)(Fig.3D). Together, this illustrates the complexity of the steroidogenic 
pathways engaged by LHR, suggesting that distinct signaling pathways might control the 
production of progesterone and testosterone as previously proposed 11. 
 
Implication of β-arrestins in progesterone production: The similarity in the partial effects of 
rhLH on β-arrestin (Fig.2A) and progesterone (Fig.3C) responses compared to rhCG suggests that 
β-arrestins may be implicated in progesterone production. Therefore, we examined the contribution 
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of β-arrestin-dependent transduction on the control of LHR-mediated steroidogenesis using siRNA-
mediated depletion of endogenous β-arrestin 1 or β-arrestin 2 in mLTC-1 cells. For this, control, β-
arrestin 1 or β-arrestin 2-depleted mLTC-1 cells were exposed to increasing doses of rhCG (Fig.4A, 
C and E) and rhLH (Fig.4B, D and F). Progesterone and testosterone were measured in parallel in 
the same cells. Our data confirm the partial progesterone response mediated by rhLH compared to 
rhCG as shown in Fig.3B. However, on testosterone production there was no difference in hormone 
efficacy but rhCG was more potent that rhLH confirming the data shown in Fig.3D. Interestingly, 
we observed that the depletion of both β-arrestin 1 and β-arrestin 2 led to a partial decrease in the 
progesterone production induced by rhCG (Fig.4A) and rhLH (Fig.4B) compared to control siRNA-
transfected mLTC-1 cells. The statistical analysis demonstrates the significance of β-arrestin 
depletion for both rhCG (p<0.0001 for siRNA β-arrestin 1 and p=0.0233 for siRNA β-arrestin 2; 
n=3) and rhLH (p=0.001 for siRNA β-arrestin 1 and p=0.0275 for siRNA β-arrestin 2; n=3) with 
siRNA β-arrestin 1 being more efficient. Moreover, β-arrestin depletion showed stronger inhibitory 
effects on testosterone production mediated by either rhCG (Fig.4C) or rhLH (Fig.4D) (p<0.0001 
for siRNA β-arrestin 1 and β-arrestin 2; n=3). The specificity of the effects of β-arrestin depletion 
on steroidogenesis was demonstrated by measuring cAMP production in parallel in the siRNA-
transfected mLTC-1 cell samples. As anticipated, the depletion of β-arrestin 1 or 2 had no effect on 
rhCG- (Fig.4E) or rhLH- (Fig.4F) mediated cAMP production whatever the dose of the hormones 
used, thus ruling out toxic or side effects that the siRNA may have exerted on these cells. Together, 
these data suggest the partial implication of β-arrestins in LHR-mediated progesterone and argue for 
a significance of β-arrestin bias between rhCG and rhLH in HEK293 cells. 
 
Calculation of biases between rhCG and rhLH: Biases were calculated using data-fitting of the 
operational model 37 and the procedure previously detailed 11,38. Bias factor combines both efficacy 
and potency to quantify the imbalance between two cell responses for an agonist, in comparison to a 
reference agonist on the same receptor and within the same cell model. For this, we used rhCG as 
the reference ligand for the different assays in both HEK293 and mLTC-1 cells (Table 3). A bias 
exists if the bias factor is significantly different from 1 (unpaired t-test). In HEK293 cells, we found 
that rhLH, compared to rhCG, was significantly biased towards cre-dependent reporter gene against 
both β-arrestin 2 and cAMP (Table 3). To some extent, rhLH is also biased towards β-arrestin 2 
against cAMP (Table 3). In other words, in HEK293 cells, rhLH preferentially induces: Cre-
dependent transcription > β-arrestin 2 recruitment > cAMP, compared to rhCG. This finding may be 
considered counterintuitive since Cre reporter assay and cAMP are connected by the activation of 
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cAMP response element-binding protein (CREB) which is primarily under the control of 
cAMP/PKA pathway. However, it is also well documented that CREB activation integrates other 
signaling pathways such as ERK and p38 MAPKs, p90RSK or CAMKs. In that sense, Cre reporter 
assay can be viewed as a read out which integrates several signalling pathways, not just 
cAMP/PKA. In mLTC-1 cells, rhLH-promoted response was significantly biased towards cAMP 
compared to progesterone and testosterone and a moderate bias appeared towards testosterone 
compared to progesterone (Table 3). This means that, in mLTC-1 cells, rhLH preferentially 
induces: cAMP > testosterone > progesterone, compared to rhCG.  Overall, these bias calculations 
confirm the differences between the pharmacological profiles of rhCG and rhLH on the different 
responses in HEK293 and mLTC-1 cells. 
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Discussion 
 
In the present work, we investigated the differential activity exerted by rhCG and rhLH upon 
binding to their common receptor, human LH/CGR transiently expressed in HEK293 cells or mouse 
LHR endogenously expressed in mLTC-1 cells. The attention was focused on comparing their 
pharmacological profiles on the heterotrimeric G proteins Gαs/cAMP pathway as well as β-
arrestins and their contribution to signal transduction mechanisms leading to the modulation of 
steroidogenesis. For cAMP, rhCG was more potent than rhLH but both hormones promoted full 
activation of the receptor at saturating doses in HEK293 as well as mLTC-1 cells. A similar 
difference in potency was also observed on β-arrestin recruitment in HEK293 cells, however an 
interesting difference was also found in hormone efficacy since rhLH promoted only a partial 
response. We also examined the action of rhLH and rhCG on progesterone and testosterone 
production in mLTC-1 cells confirming the higher potency of rhCG compared to rhLH. 
Interestingly, we found that rhLH exhibited a partial activity for progesterone compared to rhCG 
while both fully promoted testosterone production. Altogether, our data show that rhCG is more 
potent than rhLH on LH/CGR activity in HEK293 and mLTC-1 cells which is consistent with 
previous studies in COS-7 and granulosa cells 33. Moreover, the partial agonism of rhLH on 
LH/CGR on both β-arrestin recruitment and progesterone production suggests a link between these 
two events. It can be observed that the minimal doses of rhCG or rhLH promoting full testosterone 
responses trigger only very partial (20-25%) progesterone response. It reflects the physiological role 
of hCG, which serves to induce progesterone synthesis, while LH is a mediator of testosterone 
production. Indeed, in Leydig cells, androgen synthesis occurs mainly via the so-called Δ5-
pathway, while progesterone is a “parallel accumulation product” falling within the relatively 
ineffective Δ4-pathway 46. We could speculate that, differently to hCG, LH is fully active on the 
Δ5- rather than Δ4-pathway. The results provided by β-arrestins silencing by siRNA (Fig.4) agree 
with this view, since these molecules are required to fully support LH/hCG-mediated testosterone 
but not progesterone synthesis. 
In the present study, we are using immortalized cell lines as model systems. It is important 
to determine to what extent the data obtained in these cells can be indicative of the physiological 
mechanisms that occur in the ovary. In fact, the transduction mechanisms occurring directly 
downstream of the ligand-LHCGR complex, such as Gαs coupling and cAMP production or β-
arrestins recruitment, have been reported to be mostly reproducible across a wide range of cell 
models. This is corroborated by previous observation in human and goat primary granulosa cells 33-
35, in transfected COS-7 and human immortalized granulosa cell lines 33, as well as in mouse 
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primary Leydig cells 47. In all these cell systems, hCG treatment results in higher cAMP production 
than LH. One can rationalize that these mechanisms largely rely on the ligand and receptor amino 
acid sequence, conformational changes, etc., all properties that are nearly identical in granulosa and 
Leydig cells, as well as in transfected cell lines. Indeed, we demonstrated that hCG is more potent 
than LH, in terms of cAMP production, in all these cell models. The amino-acid changes existing 
between the rodent and the human receptor have been shown to have minimal, if any, effects hLH 
or hCG binding rates 23. According to this principle, downstream outputs, which are located farer 
from the ligand-receptor complex, may lead to more cell type-dependent variations. This is indeed 
the case when comparing the mLTC-1 cell line used in the present paper and the primary mouse 
Leydig cells, which were used in another recently published study 47. In primary Leydig cells, we 
demonstrated that LH and hCG treatment results in different cAMP production but equal 
testosterone dose-response curves, whereas in mLTC-1 cells, hCG is more potent than hLH at 
inducing testosterone production. Taken together, these findings indicate that hCG has a higher 
steroidogenic potential than LH, even if, in physiological settings, their effects may differ as a 
consequence of tissue-specific modulatory events. 
From the molecular point of view, LH- and hCG-induced signaling is known to be 
differently modulated by exon 10 deletion in LH/CGR, which results in structural and spatial 
rearrangements at the hinge region of the receptor 32. In the presence of this deletion, LH signaling 
is impaired while hCG signaling remain unchanged, suggesting divergences between hCG- and LH-
receptor interactions and actions. In addition, hCG and LH were recently shown to interact 
differently with the hinge region of the receptor 25 and only hCG is capable of inducing both cis- 
and trans-activation of human LH/CGR 26. Moreover, both hCG and LH were reported to have 
similar association rate on rat LHR (3 x 108 M-1.min-1) but different dissociation rate (25 h for hCG 
and ∼9 h for hLH) constants indicating higher residence time of hCG on its receptor 23. Such a 
finding was recently supported by dissociation assays on gonadotropin-promoted cAMP production 
in mLTC-1, suggesting weaker dissociation of hCG from LHR compared to hLH 36. Furthermore, 
our real-time cAMP measurements clearly showed differences in the kinetics of the two hormones 
with rhCG inducing faster cAMP responses than rhLH. This indicates the relationship between the 
difference in hormone potencies and the kinetics of their induced responses, suggesting a link 
between pharmacological bias and response kinetics as recently reported 48. Collectively, these 
observations suggest that the slower dissociation rate of rhCG compared to that of rhLH and/or the 
differences in the conformations of hormone-receptor complexes may explain the differences 
between rhCG- and rhLH-promoted responses.  
 16
Our quantitative pharmacological profiling revealed striking peculiarities when comparing 
the maximal responses elicited by the two gonadotropins on the different readouts. Indeed, even 
though identical maximal cAMP responses were reached with either gonadotropin, whatever the 
cell type (HEK293 and mLTC-1), rhLH led to significantly weaker maximal β-arrestin 2 
recruitment and progesterone production than rhCG. Thus, it could be hypothesized that β-arrestin 
is a limiting factor for maximal progesterone production. In other words, rhLH like rhCG is full 
agonist on LH/CGR for cAMP and testosterone production, whereas it is only partial agonist for β-
arrestin recruitment and progesterone production. The fact that rhLH was full agonist on 
testosterone and had only a partial efficacy on progesterone further demonstrates that the full action 
of the hormone, in Leydig cells, is exerted via Δ5-pathway, through 17-OH-pregnenolone 
production (instead of progesterone) as a precursor of testosterone. This is also supported by our 
recent study using two FSHR and LHR negative allosteric modulators (NAMs) showing differential 
antagonism of the two NAMs on progesterone and testosterone 11. Moreover, we observed that both 
hormones differently affected the conformation of β-arrestin 2 as assessed in double brilliance 
BRET assay used as conformational sensor of β-arrestins 40,42. In this assay, rhCG elicited less 
BRET changes within the β-arrestin 2 sensor than rhLH which is consistent with the idea that the 
two hormones stabilize different conformations of β-arrestin as shown for other GPCRs depending 
on the ligands applied 41,49,50. 
Together, these observations strongly suggest that rhCG and LH differentially recruit ß-
arrestins and activate downstream pathways which may control progesterone production. We 
hypothesized that β-arrestin-dependent transduction could be involved in the control of the balance 
between progesterone and testosterone production as recently reported 11. Supporting this view, we 
demonstrated that depletion of endogenous β-arrestins in mLTC-1 cells using selective siRNA led 
indeed to partially but significantly reduced progesterone production. This supports the link 
between the partial agonism of rhLH on both β-arrestin and progesterone production. In contrast, 
such depletion had no effect on hormone-promoted cAMP production in mLTC-1 excluding a role 
of β-arrestins in cAMP production as expected. Altogether, our results support to the concept of 
biased agonism exerted by rhCG and rhLH and bear the notion that LH/CGR can discriminate the 
binding of the two hormones, thereby triggering different transduction mechanisms hence 
intracellular responses. In addition to the pharmacological profiling of rhCG and rhLH, our study 
and the bias analysis reveal the importance to quantify the balance between the different signaling 
pathways for each hormone. The fact that both hormones naturally coexist but to different extent 
and at different stages during folliculogenesis and pregnancy, raises intriguing prospects. The use of 
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these hormones in assisted reproduction could also be impacted by the present findings. Finally, the 
impact of our study goes beyond the gonadotropin receptors and reproduction since it describes an 
interesting example of biased signaling involving two endogenous hormones activating a common 
GPCR. This further demonstrates the physiological relevance of the signaling bias at GPCRs with 
strong impact on our understanding of GPCR pharmacology and signaling and potential 
applications in drug discovery programs 51,52. 
 
 
 18
Acknowledgements 
This work has been funded by Région Centre ARD2020 Biomédicaments. LR is funded by 
Associazione Scientifica in Endocrinologia, Andrologia e Metabolismo and Erasmus+ Grant. MAA 
is funded by LE STUDIUM® Loire Valley Institute for Advanced Studies and AgreenSkills Plus. 
 
Disclosure Statement 
The authors have nothing to disclose. 
 19
References 
 
1. Arey, B. J. & Lopez, F. J. Are circulating gonadotropin isoforms naturally occurring biased 
agonists? Basic and therapeutic implications. Rev Endocr Metab Disord 12, 275-288, 
doi:10.1007/s11154-011-9188-y (2011). 
2. Bousfield, G. R. & Dias, J. A. Synthesis and secretion of gonadotropins including structure-
function correlates. Rev Endocr Metab Disord 12, 289-302, doi:10.1007/s11154-011-9191-3 
(2011). 
3. Leão, R. B. & Esteves, S. C. Gonadotropin therapy in assisted reproduction: an evolutionary 
perspective from biologics to biotech. Clinics (Sao Paulo) 69, 279-293 (2014). 
4. Ascoli, M., Fanelli, F. & Segaloff, D. L. The lutropin/choriogonadotropin receptor, a 2002 
perspective. Endocrine reviews 23, 141-174, doi:10.1210/edrv.23.2.0462 (2002). 
5. Choi, J. & Smitz, J. Luteinizing hormone and human chorionic gonadotropin: distinguishing 
unique physiologic roles. Gynecol Endocrinol 30, 174-181, doi:10.3109/09513590.2013.859670 
(2014). 
6. Gudermann, T., Birnbaumer, M. & Birnbaumer, L. Evidence for dual coupling of the murine 
luteinizing hormone receptor to adenylyl cyclase and phosphoinositide breakdown and Ca2+ 
mobilization. Studies with the cloned murine luteinizing hormone receptor expressed in L cells. J 
Biol Chem 267, 4479-4488 (1992). 
7. Gudermann, T., Nichols, C., Levy, F. O., Birnbaumer, M. & Birnbaumer, L. Ca2+ mobilization 
by the LH receptor expressed in Xenopus oocytes independent of 3',5'-cyclic adenosine 
monophosphate formation: evidence for parallel activation of two signaling pathways. Mol 
Endocrinol 6, 272-278, doi:10.1210/mend.6.2.1314958 (1992). 
8. Ulloa-Aguirre, A., Crepieux, P., Poupon, A., Maurel, M. C. & Reiter, E. Novel pathways in 
gonadotropin receptor signaling and biased agonism. Rev Endocr Metab Disord 12, 259-274, 
doi:10.1007/s11154-011-9176-2 (2011). 
9. Nakamura, K., Lazari, M. F., Li, S., Korgaonkar, C. & Ascoli, M. Role of the rate of 
internalization of the agonist-receptor complex on the agonist-induced down-regulation of the 
lutropin/choriogonadotropin receptor. Molecular endocrinology 13, 1295-1304, 
doi:10.1210/mend.13.8.0331 (1999). 
10. Ayoub, M. A. et al. Assessing Gonadotropin Receptor Function by Resonance Energy 
Transfer-Based Assays. Front Endocrinol (Lausanne) 6, 130, doi:10.3389/fendo.2015.00130 
(2015). 
11. Ayoub, M. A. et al. Profiling of FSHR negative allosteric modulators on LH/CGR reveals 
biased antagonism with implications in steroidogenesis. Molecular and cellular endocrinology 
436, 10-22, doi:10.1016/j.mce.2016.07.013 (2016). 
12. Lefkowitz, R. J. & Shenoy, S. K. Transduction of receptor signals by beta-arrestins. Science. 
308, 512-517 (2005). 
13. Reiter, E. & Lefkowitz, R. J. GRKs and beta-arrestins: roles in receptor silencing, trafficking 
and signaling. Trends Endocrinol Metab 17, 159-165 (2006). 
14. Reiter, E., Ahn, S., Shukla, A. K. & Lefkowitz, R. J. Molecular mechanism of beta-arrestin-
biased agonism at seven-transmembrane receptors. Annu Rev Pharmacol Toxicol 52, 179-197, 
doi:10.1146/annurev.pharmtox.010909.105800 (2012). 
15.  Casarini, L., Reiter, E. & Simoni, M. beta-arrestins regulate gonadotropin receptor-mediated 
cell proliferation and apoptosis by controlling different FSHR or LHCGR intracellular signaling 
in the hGL5 cell line. Molecular and cellular endocrinology 437, 11-21, 
doi:10.1016/j.mce.2016.08.005 (2016). 
16. Galet, C. & Ascoli, M. Arrestin-3 is essential for the activation of Fyn by the luteinizing 
hormone receptor (LHR) in MA-10 cells. Cellular signalling 20, 1822-1829, 
doi:10.1016/j.cellsig.2008.06.005 (2008). 
 20
17. Krishnamurthy, H., Galet, C. & Ascoli, M. The association of arrestin-3 with the follitropin 
receptor depends on receptor activation and phosphorylation. Molecular and cellular 
endocrinology 204, 127-140 (2003). 
18. Neill, J. D., Duck, L. W., Musgrove, L. C. & Sellers, J. C. Potential regulatory roles for G 
protein-coupled receptor kinases and beta-arrestins in gonadotropin-releasing hormone receptor 
signaling. Endocrinology 139, 1781-1788 (1998). 
19. Wehbi, V. et al. Partially deglycosylated equine LH preferentially activates beta-arrestin-
dependent signaling at the follicle-stimulating hormone receptor. Molecular endocrinology 24, 
561-573, doi:10.1210/me.2009-0347 (2010). 
20. Tranchant, T. et al. Preferential beta-arrestin signalling at low receptor density revealed by 
functional characterization of the human FSH receptor A189 V mutation. Molecular and cellular 
endocrinology 331, 109-118, doi:10.1016/j.mce.2010.08.016 (2011). 
21. Kara, E. et al. A phosphorylation cluster of five serine and threonine residues in the C-terminus 
of the follicle-stimulating hormone receptor is important for desensitization but not for beta-
arrestin-mediated ERK activation. Molecular endocrinology 20, 3014-3026, 
doi:10.1210/me.2006-0098 (2006). 
22. Khan-Sabir, N., Beshay, V. E. & Carr, B. R. in Endotext Vol. chapter 3   (2008). 
23. Huhtaniemi, I. T. & Catt, K. J. Differential binding affinities of rat testis luteinizing hormone 
(LH) receptors for human chorionic gonadotropin, human LH, and ovine LH. Endocrinology 
108, 1931-1938, doi:10.1210/endo-108-5-1931 (1981). 
24. Galet, C. & Ascoli, M. The differential binding affinities of the luteinizing hormone 
(LH)/choriogonadotropin receptor for LH and choriogonadotropin are dictated by different 
extracellular domain residues. Mol Endocrinol 19, 1263-1276, doi:10.1210/me.2004-0410 
(2005). 
25. Grzesik, P. et al. Differences in Signal Activation by LH and hCG are Mediated by the LH/CG 
Receptor's Extracellular Hinge Region. Front Endocrinol (Lausanne) 6, 140, 
doi:10.3389/fendo.2015.00140 (2015). 
26. Grzesik, P. et al. Differences between lutropin-mediated and choriogonadotropin-mediated 
receptor activation. FEBS J 281, 1479-1492, doi:10.1111/febs.12718 (2014). 
27. Choi, J. & Smitz, J. Luteinizing hormone and human chorionic gonadotropin: origins of 
difference. Molecular and cellular endocrinology 383, 203-213, doi:10.1016/j.mce.2013.12.009 
(2014). 
28. Galandrin, S., Oligny-Longpre, G. & Bouvier, M. The evasive nature of drug efficacy: 
implications for drug discovery. Trends Pharmacol Sci 28, 423-430 (2007). 
29. Kenakin, T. Functional selectivity through protean and biased agonism: who steers the ship? 
Mol Pharmacol 72, 1393-1401, doi:10.1124/mol.107.040352 (2007). 
30. Landomiel, F. et al. Biased signalling in follicle stimulating hormone action. Molecular and 
cellular endocrinology 382, 452-459, doi:10.1016/j.mce.2013.09.035 (2014). 
31. Gromoll, J., Eiholzer, U., Nieschlag, E. & Simoni, M. Male hypogonadism caused by 
homozygous deletion of exon 10 of the luteinizing hormone (LH) receptor: differential action of 
human chorionic gonadotropin and LH. J Clin Endocrinol Metab 85, 2281-2286, 
doi:10.1210/jcem.85.6.6636 (2000). 
32. Muller, T., Gromoll, J. & Simoni, M. Absence of exon 10 of the human luteinizing hormone 
(LH) receptor impairs LH, but not human chorionic gonadotropin action. J Clin Endocrinol 
Metab 88, 2242-2249, doi:10.1210/jc.2002-021946 (2003). 
33. Casarini, L. et al. LH and hCG action on the same receptor results in quantitatively and 
qualitatively different intracellular signalling. PLoS One 7, e46682, 
doi:10.1371/journal.pone.0046682 (2012). 
34. Casarini, L. et al. Follicle-stimulating hormone potentiates the steroidogenic activity of 
chorionic gonadotropin and the anti-apoptotic activity of luteinizing hormone in human 
 21
granulosa-lutein cells in vitro. Molecular and cellular endocrinology 422, 103-114, 
doi:10.1016/j.mce.2015.12.008 (2016). 
35. Gupta, C. et al. Differential response to sustained stimulation by hCG & LH on goat ovarian 
granulosa cells. The Indian journal of medical research 135, 331-340 (2012). 
36. Klett, D. et al. Low reversibility of intracellular cAMP accumulation in mouse Leydig tumor 
cells (MLTC-1) stimulated by human Luteinizing Hormone (hLH) and Chorionic Gonadotropin 
(hCG). Molecular and cellular endocrinology 434, 144-153, doi:10.1016/j.mce.2016.06.028 
(2016). 
37. Black, J. W. & Leff, P. Operational models of pharmacological agonism. Proc R Soc Lond B 
Biol Sci 220, 141-162 (1983). 
38. van der Westhuizen, E. T., Breton, B., Christopoulos, A. & Bouvier, M. Quantification of ligand 
bias for clinically relevant beta2-adrenergic receptor ligands: implications for drug taxonomy. 
Molecular Pharmacology 85, 492-509, doi:10.1124/mol.113.088880 (2014). 
39. Kovacs, J. J. et al. Beta-arrestin-mediated localization of smoothened to the primary cilium. 
Science 320, 1777-1781, doi:10.1126/science.1157983 (2008). 
40. Charest, P. G., Terrillon, S. & Bouvier, M. Monitoring agonist-promoted conformational 
changes of beta-arrestin in living cells by intramolecular BRET. EMBO Rep 6, 334-340, 
doi:7400373 [pii] 10.1038/sj.embor.7400373 (2005). 
41. Lee, M. H. et al. The conformational signature of beta-arrestin2 predicts its trafficking and 
signalling functions. Nature 531, 665-668, doi:10.1038/nature17154 (2016). 
42. Kamal, M. et al. Improved donor/acceptor BRET couples for monitoring beta-arrestin 
recruitment to G protein-coupled receptors. Biotechnol J, doi:10.1002/biot.200900016 (2009). 
43. Troispoux, C. et al. Involvement of G protein-coupled receptor kinases and arrestins in 
desensitization to follicle-stimulating hormone action. Molecular endocrinology 13, 1599-1614, 
doi:10.1210/mend.13.9.0342 (1999). 
44. Canepa, S. et al. Validation d’une méthode immunoenzymatique pour le dosage de la 
progesterone dans le plasma des ovins et des bovins. Cahiers techniques de l’INRA 64, 19-30 
(2008). 
45. Rebois, R. V. Establishment of gonadotropin-responsive murine leydig tumor cell line. The 
Journal of cell biology 94, 70-76 (1982). 
46. Miller, W. L. & Auchus, R. J. The molecular biology, biochemistry, and physiology of human 
steroidogenesis and its disorders. Endocrine Reviews 32, 81-151, doi: 10.1210/er.2010-0013 
(2011). 
47. Riccetti, L. et al. Human LH and hCG stimulate differently the early signalling pathways but 
result in equal testosterone synthesis in mouse Leydig cells in vitro. Reprod Biol Endocrinol. 15, 
2, doi: 10.1186/s12958-016-0224-3 (2017). 
48. Klein Herenbrink, C. et al. The role of kinetic context in apparent biased agonism at GPCRs. 
Nat Commun 7, 10842, doi:10.1038/ncomms10842 (2016). 
49. Shukla, A. K. et al. Distinct conformational changes in beta-arrestin report biased agonism at 
seven-transmembrane receptors. Proceedings of the National Academy of Sciences of the United 
States of America 105, 9988-9993, doi:10.1073/pnas.0804246105 (2008). 
50. Nuber, S. et al. beta-Arrestin biosensors reveal a rapid, receptor-dependent 
activation/deactivation cycle. Nature 531, 661-664, doi:10.1038/nature17198 (2016). 
51. Kenakin, T. & Christopoulos, A. Signalling bias in new drug discovery: detection, 
quantification and therapeutic impact. Nature reviews. Drug discovery 12, 205-216, 
doi:10.1038/nrd3954 (2013). 
52. Luttrell, L. M. Minireview: More than just a hammer: ligand "bias" and pharmaceutical 
discovery. Molecular endocrinology 28, 281-294, doi:10.1210/me.2013-1314 (2014). 
 22
Author contribution statement 
"L.R. and M.A.A. designed and performed most of the BRET and FRET experiments, wrote the 
main manuscript text, and prepared the figures and tables; R.Y. performed bias calculations; D.K 
and Y.C. contributed to steroid measurements;  N.G. contributed to siRNA experiments; E.R., M.S., 
and L.C. designed the experiments and wrote the manuscript. All authors reviewed the manuscript." 
 
 
 23
Table 1: Efficacy (Emax) and efficiency (EC50) of rhCG and rhLH on LH/CGR measured in 
different assays in HEK293 cells. The Emax values are represented as hormone-induced BRET 
changes (for cAMP and ß-arrestin 2) and relative luciferase activity x 103 (for Cre-reporter assay). 
Statistical analyses were performed with unpaired t-test (*** p < 0.001; ** p < 0.01; * p < 0.05, ns 
non-significant). 
Responses rhCG  
      Emax                         EC50                          n 
rhLH 
    Emax                        EC50                                            n  
cAMP 0.43 ± 0.02            17.64 ± 6.97 pM              8 0.42 ± 0.01ns         286.49 ± 50.29 pM***           8 
ß-arrestin 2 0.21 ± 0.01            10.26 ± 2.50 nM              5 0.14 ± 0.01**         129.10 ± 69.96 nM*             5  
Cre-reporter 
assay 
222.12 ± 9.64        37.47 ± 4.94 pM              3 214.03 ± 9.58ns     215.45 ± 20.81 pM***           3 
 
Table 2: Efficacy (Emax) and efficiency (EC50) of rhCG and rhLH on LHR measured in 
different assays in mLTC-1 cells. The Emax values are represented as hormone-induced BRET 
changes (for cAMP by BRET), % of rhCG-induced response (for cAMP by HTRF, progesterone 
and testosterone) and relative luciferase activity (for Cre-reporter assay). Statistical analyses were 
performed with unpaired t-test (*** p < 0.001; ** p < 0.01; * p < 0.05, ns non-significant). 
Responses rhCG  
     Emax                          EC50                          n 
rhLH 
    Emax                        EC50                                            n  
cAMP (BRET) 0.45 ± 0.02            68.82 ± 22.30 pM             5 0.44 ± 0.02ns              459 ± 105.35 pM**          5 
cAMP (HTRF)     100%                 97.37 ± 47.15 pM            3 102 ± 5.8%ns       1980.33 ± 868.64 pM*           3 
Cre-reporter 
assay 
1910 ± 111            24.97 ± 16.20 pM            4 1971 ± 168ns         317.62 ± 210.70 pM*           4 
Progesterone     100%                 19.72 ± 4.28 pM              3 49.78 ± 2.90%***  305.83 ± 25.22 pM**            3  
Testosterone     100%                   2.19 ± 0.91 pM              4 93.33 ± 6.5%ns       29.05 ± 6.90 pM**              4  
 
Table 3: Bias factor on the different responses in HEK293 and mLTC-1 cells. The bias factor 
values of each response pair reflect the biased agonism of rhLH towards the first response 
compared to the second, all in comparison to rhCG taken as the reference hormone. 
HEK293 cells Bias factor mLTC-1 cells Bias factor 
ß-arrestin 2 / cAMP  1.81 (p=0.0655) cAMP / Progesterone 5.25 (p=0.0034) 
Cre-reporter assay / cAMP 4.84 (p=0.0000177) cAMP / Testosterone 2.39 (p=0.0301) 
Cre-reporter assay / ß-arrestin 2 2.67 (p=0.00988) Testosterone / Progesterone 2.19 (p=0.0617) 
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Figure Legends 
 
Figure 1: LH/CGR-mediated cAMP production. cAMP responses induced by rhCG and rhLH in 
HEK293 cells transiently co-transfected with hLH/CGR and CAMYEL sensor (A, B) and in 
mLTC-1 cells transiently transfected with CAMYEL sensor alone (C) or not (D). Cells were 
stimulated 30 minutes with increasing doses (A, C and D) or immediately with the indicated doses 
(B) of rhCG and rhLH, before cAMP production was measured by BRET (A, B and C) or HTRF 
(D). Data are means ± SEM of 3-8 independent experiments. The kinetic curves in panel B are 
representative of 3 experiments performed in triplicate.  
 
Figure 2: LH/CGR-promoted β-arrestin 2 recruitment and activation in HEK293 cells. 
HEK293 cells transiently co-expressing either hLH/CGR-Rluc8 and yPET-β-arrestin 2 (A and B) or 
wildtype hLHR/CGR and Rluc8-β-arrestin 2-RGFP (C) were stimulated 30 minutes with increasing 
doses (A and D) or immediately with the indicated doses (B) or 0.25 µM (C) of rhCG and rhLH 
before BRET was measured. Data are means ± SEM of 3-5 independent experiments. The kinetic 
curves in panel B are representative of 3 experiments performed in triplicate.  
 
Figure 3: LH/CGR-promoted integrated responses in HEK293 and mLTC-1 cells. A) HEK293 
transiently co-transfected with plasmids coding for LH/CGR and pSOM-Luc reporter gene were 
stimulated 6 hours with increasing doses of rhCG and rhLH before luciferase activity was measured 
(A). mLTC-1 cells transiently transfected with plasmid coding pSOM-Luc reporter gene were 
stimulated 6 hours with increasing doses of rhCG and rhLH before luciferase activity was measured 
(B). For LHR-mediated steroid production, mLTC-1 cells were stimulated 3 hours with increasing 
doses of rhCG and rhLH and the supernatant levels of progesterone (C) and testosterone (D) were 
measured by ELISA or HTRF, respectively. Data are means ± SEM of 3-5 independent experiments 
performed in single or duplicate.   
 
Figure 4: Implication of β-arrestins in LH/CGR-promoted steroid production in mLTC-1 
cells. mLTC-1 cells were transiently transfected with either control, β-arrestin 1 or β-arrestin 2 
siRNAs. Then, cells were stimulated 3 hours with increasing doses of rhCG (A, C and E) and rhLH 
(B, D and F) before progesterone (A and B), testosterone (C and D) and cAMP (E and F) 
productions were measured. The maximal rhCG-mediated responses obtained at 10 nM with control 
siRNA was taken as 100%. Data are means ± SEM of 3 independent experiments performed in 
duplicate.  




